Insmed

+$1.57 (+7.91%) Today

$0.00 (0.00%) As of 9:42 PM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Insmed and other ETFs, options, and stocks.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.

CEO

William H. Lewis

Employees

613

Headquarters

Bridgewater, New Jersey

Founded

1988

INSM Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

1.26M

High today

$21.50

Low today

$19.89

Open price

$20.10

Volume

2.17M

52 Week high

$34.44

52 Week low

$16.41

INSM News

Simply Wall StJun 24

Is Insmed A Risky Investment? - Simply Wall St

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural t

Analyst ratings

Buy

100%

Hold

Sell

INSM Earnings

-$1.00

-$0.67

-$0.33

$0.00

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Estimated

— per share

Actual

Expected Aug 4, Pre-Market

Why Robinhood?

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. View more

Is Insmed A Risky Investment? - Simply Wall St

100%

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.